A Phase IIa Study to Evaluate the Efficacy and Safety of 6MW3211 in Patients With Advanced Lung Cancer Who Had Failed Therapy With PD-1/L1 Inhibitor
Latest Information Update: 06 Jun 2024
At a glance
- Drugs 6MW 3211 (Primary)
- Indications Non-small cell lung cancer; Small cell lung cancer
- Focus Therapeutic Use
Most Recent Events
- 28 Jun 2022 New trial record